The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Angela Jia discussing the clinical ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy radiotherapy. The study demonstrated an improvement in 3-year freedom from ...

Dr. Yu began by highlighting that moderately hypofractionated IMRT (MH-IMRT) has been the standard of care for prostate cancer since RTOG 0415 and other landmark studies. 1 At the time this trial was ...

The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco., between September 28 and September 30 was host to the Session16 - GU 4: Quality of Life Outcomes after ...

The 2025 ASTRO annual meeting featured a prostate cancer radiation toxicity session and a presentation by Dr. Young Suk Kwon discussing an EPIC-26 longitudinal analyses of prostatic urethral lift ...

The MARCAP Consortium is the largest independent data repository and statistical analysis team, with Dr. Spratt and Dr. Amar Kishan as co-primary investigators. The purpose of the first MARCAP ...

ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy ...

Stereotactic body radiation therapy (SBRT), defined as the delivery of >5Gy per fraction, has emerged as a well-established standard of care option for the definitive management of localized prostate ...

This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center between October 2019 and April 2024 and had ≥1 post-TMT ctDNA (Signatera TM) ...